Literature DB >> 12371972

Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide.

Gary L Schwartz1, Stephen T Turner, Arlene B Chapman, Eric Boerwinkle.   

Abstract

BACKGROUND: Genetic factors may influence blood pressure (BP) response to diuretic therapy through their effects on activity of the renin-angiotensin-aldosterone system (RAAS). The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene is associated with variation in serum ACE activity and may influence BP in a gender-specific manner.
METHODS: We measured the I/D polymorphism in 206 non-Hispanic women (130 blacks, 76 whites) and 170 non-Hispanic men (62 blacks, 108 whites) with essential hypertension (age 48 +/- 7 years, mean +/- SD) who underwent monotherapy with hydrochlorothiazide (HCTZ) 25 mg daily for four weeks.
RESULTS: In both genders, serum ACE activity increased in a co-dominant fashion in association with the D-allele (P < 0.001 for both genders). In regression models that considered the effects of baseline BP, race, gender, age, waist-to-hip ratio, and measures of the RAAS, there was significant interaction between the effects of the ACE genotype and gender on the responses of both systolic and diastolic BP to HCTZ (for systolic BP response, P = 0.03; for diastolic BP response, P = 0.001). Among women, mean declines in systolic and diastolic BP were greater in II than in DD homozygotes; whereas among men, mean declines in systolic and diastolic BP were greater in DD than in II homozygotes. In models that included the effects of race, gender, age, and waist-to-hip ratio, there was also significant interaction between the effects of the ACE genotype and gender on pre-treatment urinary aldosterone excretion (P = 0.01) and change in urinary aldosterone excretion in response to HCTZ (P = 0.007). The genotypes that were associated with the greatest BP responses to HCTZ (II homozygotes in women and DD homozygotes in men) had the lowest pre-treatment urinary aldosterone excretion and the greatest increase in urinary aldosterone excretion in response to HCTZ.
CONCLUSION: The relationship between the ACE I/D polymorphism and antihypertensive response to a standard dose of HCTZ differs significantly between women and men. Because the D-allele was associated with significant, co-dominant increases in serum ACE activity in both genders, the gender-specific effects of the I/D polymorphism on BP response to HCTZ may be mediated subsequent to the enzymatic generation of angiotensin II.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371972     DOI: 10.1046/j.1523-1755.2002.00624.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

Review 1.  Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Authors:  Hedi Schelleman; Bruno H Ch Stricker; Anthonius De Boer; Abraham A Kroon; Monique W M Verschuren; Cornelia M Van Duijn; Bruce M Psaty; Olaf H Klungel
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Pharmacogenetics of antihypertensive drug response.

Authors:  Reinhold Kreutz
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 3.  Personalized medicine for high blood pressure.

Authors:  Stephen T Turner; Gary L Schwartz; Eric Boerwinkle
Journal:  Hypertension       Date:  2007-04-30       Impact factor: 10.190

Review 4.  Genetics of the human renin angiotensin system.

Authors:  Xavier Jeunemaitre
Journal:  J Mol Med (Berl)       Date:  2008-04-29       Impact factor: 4.599

Review 5.  Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

Authors:  Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  The Alu polymorphism of angiotensin I converting enzyme (ACE) and atherosclerosis, incident chronic diseases and mortality in an elderly Chinese population.

Authors:  J Woo; N L S Tang; J Leung; T Kwok
Journal:  J Nutr Health Aging       Date:  2012-03       Impact factor: 4.075

Review 7.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

8.  Sex-specific effects of ACE I/D and AGT-M235T on pulse pressure: the HyperGEN Study.

Authors:  Amy I Lynch; Donna K Arnett; James S Pankow; Michael B Miller; Kari E North; John H Eckfeldt; Steven C Hunt; Dabeeru C Rao; Luc Djoussé
Journal:  Hum Genet       Date:  2007-05-10       Impact factor: 4.132

9.  PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

Review 10.  Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.

Authors:  Flavia Franconi; Ilaria Campesi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.